Dual antihypertensive combinations after PCI: ARB + thiazide versus ARB + amlodipine
Official title: Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
Run by National Medical Research Center for Therapy and Preventive Medicine · NCT07683585 · Data updated 2026-11-12
This trial tests two blood pressure treatment combos after a stent procedure in people with hypertension and coronary disease to see which regimen better controls blood pressure and improves symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 70 Years |
| Sex | All |
| Enrollment | 207 (estimated) |
| Sponsor | National Medical Research Center for Therapy and Preventive Medicine Government |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | July 2026 |
| Study ends | September 2026 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT07683585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–70 with hypertension and coronary artery disease who had elective PCI with stenting and require dual antihypertensive therapy.
✕Probably not a fit
Patients who do not respond to dual therapy or who experience adverse reactions or contraindications to ARB, thiazide diuretic, or amlodipine may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective randomized, open-label study compares two dual antihypertensive regimens in adults with hypertension and coronary artery disease who recently underwent elective PCI with coronary stenting. Participants are randomized to receive either an ARB plus a thiazide diuretic or an ARB plus a dihydropyridine calcium channel blocker, and are followed after discharge at 2, 4, and 12 weeks via in-person or telemedicine visits. Primary endpoint is the percentage reduction in systolic and diastolic blood pressure, with secondary endpoints including angina frequency, exercise capacity, quality of life, need for treatment intensification, and healthcare utilization. Safety and tolerability are monitored through the follow-up period. The study uses standard post-PCI care alongside dual antihypertensive therapy to assess comparative effectiveness.
Why it matters
Potential benefit: If successful, this approach could clarify which dual regimen provides better blood pressure control and symptom relief after PCI, potentially guiding more effective outpatient management.
How similar studies have gone: Previous studies have explored dual regimens post-PCI but this direct ARB + thiazide versus ARB + amlodipine comparison in this specific post-PCI population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 50 to 70 years * Arterial hypertension * Coronary artery disease * Hospitalization for elective percutaneous coronary intervention * Coronary artery stenting during the current hospitalization * Requirement for dual antihypertensive therapy * Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy * Ability and willingness to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Acute coronary syndrome * Active malignancy * Pulmonary embolism * Chronic kidney disease stage 4-5 * Type 2 diabetes mellitus * Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout * Women of reproductive age * Permanent or persistent atrial fibrillation * Planned staged coronary stenting * Heart failure with reduced ejection fraction * Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results
Where it's running
-
National Medical Research Center for Therapy and Preventive Medicine
Moscow, Russia Recruiting
Study contacts
- Principal investigator: Oxana Drapkina — National Medical Research Center for Therapy and Preventive Medicine
- Study coordinator: Elizaveta Rogozhkina
- Email: lizarogozkina@gmail.com
- Phone: +7 (937) 104-73-31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using low-dose aspirin after preeclampsia to improve recovery
This study is testing if taking low-dose aspirin for six months after having preeclampsia can help new moms recover better by improving their blood pressure and blood vessel function.
-
IMB-guided health education to boost medication taking and blood pressure control in adults with hypertension
This study tests a health-literacy program based on Information-Motivation-Behavioral Skills to help adults with hypertension who don’t take their medicines regularly to take them more consistently and better control their blood pressure.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Hypertension: Does Education Help Patients Manage Blood Pressure Better?
This study tests whether structured patient education improves blood pressure control and self-management in adults with hypertension who speak Turkish.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Long-term GW906 treatment for people with essential hypertension
This trial tests whether long-term GW906 injections are safe and effective for adults with essential hypertension who completed an earlier GW906 study.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.